Melanoma News and Research

Latest Melanoma News and Research

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

30 Aug 2011

Men reluctant to use sunscreen- survey

A new survey claims that less than half of men use sunscreen of at least factor 15 to protect their skin from damage.

30 Aug 2011

Ecstasy redesigned for use against blood cancer

The illicit drug ecstasy has been redesigned by researchers at the University of WA for use in treatment of blood cancers.

30 Aug 2011

Men worse than women at protecting their skin in the sun

Nearly 90 per cent of British adults admit their skin has been sunburnt - with almost half experiencing pain as result of being in the sun.

29 Aug 2011

Individuals with BAP1 gene mutation more likely to develop mesothelioma

Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer - mesothelioma, and melanoma of the eye.

29 Aug 2011

Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.

24 Aug 2011

New advances in genomics, molecular diagnostics to be showcased at CAP 2011 meeting

The latest developments in molecular diagnostics, personalized medicine, and genetics testing will be featured topics when more than 1,000 pathologists gather at the Gaylord Texan on September 11 – 14 for the annual scientific meeting of the College of American Pathologists.

24 Aug 2011

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

IsoRay, Inc. said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

23 Aug 2011

Wistar Institute, Graham Cancer Center enter research collaboration

Christiana Care Health System's Helen F. Graham Cancer Center and The Wistar Institute, an international leader in biomedical research, have entered into an historic partnership to collaborate on translational cancer research with the aim of bringing the latest discoveries in cancer research to cancer patients in the community.

20 Aug 2011

Powerful X-rays help develop new drug treatment for malignant melanoma

Powerful X-ray technology developed at the U.S. Department of Energy's (DOE's) national laboratories is revealing new insights into diseases ranging from Alzheimer's to the swine flu, and, most recently, enabled the discovery of a groundbreaking new drug treatment for malignant melanoma, the deadliest form of skin cancer.

19 Aug 2011

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

A new drug was approved for advanced skin cancer this Wednesday by U.S. regulators, offering the first new treatment for melanoma in 13 years.

18 Aug 2011

Roche receives FDA approval for Zelboraf to treat BRAF mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.

18 Aug 2011

Zelboraf receives FDA approval for treatment of metastatic melanoma

The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

17 Aug 2011

Health Canada grants medical device license to Gen-Probe's PROGENSA PCA3 assay

Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.

17 Aug 2011

Caffeine might help prevent skin cancer

A new Rutgers study strengthens the theory that caffeine guards against certain skin cancers at the molecular level by inhibiting a protein enzyme in the skin, known as ATR. Scientists believe that based on what they have learned studying mice, caffeine applied directly to the skin might help prevent damaging UV light from causing skin cancer.

16 Aug 2011

Caffeine in sunscreens may protect from skin cancer: Study

Studies have revealed that drinking caffeinated beverages reduces one’s chances of developing some types of cancer, including UV-associated skin cancer. Now, researchers propose a possible mechanism for this observation—the inhibition of a DNA repair pathway that sensitizes cells to death after sun exposure.

15 Aug 2011

Galectin second quarter net loss increases to $3.9 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months, ended June 30, 2011.

12 Aug 2011

Tanning beds may spur addictive neurological reward and reinforcement trigger

People who frequently use tanning beds may be spurred by an addictive neurological reward-and-reinforcement trigger, researchers at UT Southwestern Medical Center have found in a pilot study.

12 Aug 2011

Gene therapy to combat leukemia

In a medical breakthrough scientists have found that gene therapy could be used to cure leukemia. Researchers at the University of Pennsylvania engineered patients' own pathogen-fighting T-cells to target a molecule found on the surface of leukemia cells. These genetically modified T-cells were grown outside of the body and infused back into patients suffering from late-stage chronic lymphocytic leukemia (CLL), which affects the blood and bone marrow and is the most common form of leukemia.

11 Aug 2011

Neoprobe seeks FDA marketing approval of Lymphoseek for use in ILM oncology procedure

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced it has submitted a New Drug Application (NDA) for Lymphoseek to the U.S. Food and Drug Administration.

11 Aug 2011